Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer

Novel therapies in multiple myeloma

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma

Cabozantinib in combination with atezolizumab in patients with mCRPC

ESMO President: What to watch for at ESMO 2021

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy

Idecabtagene vicleucel for relapsed and refractory multiple myeloma